Exclusive Summary

• **Next-Gen ADC Mechanism**: UB431 features a unique "Bispecific Antibody + Dual-payload" design that utilizes synergistic killing mechanisms (e.g., DNA damage + Microtubule inhibition) to effectively overcome tumor heterogeneity and drug resistance compared to traditional ADCs.
• **Targeting Refractory Tumors**: Specifically targeting DLL3-expressing SCLC, the bispecific structure enhances internalization efficiency and addresses resistance caused by antigen downregulation, meeting the critical unmet need for 2nd-line SCLC treatments.
• **Proprietary Tech Platform**: Built on Unibest's exclusive "One-Linker-Two-Payload (L2P)" technology, UB431 achieves a homogeneous Drug-to-Antibody Ratio (DAR) and a wider therapeutic window, offering superior CMC controllability compared to combination therapies.

Asset Materials

Contact Us for Full Materials